(Health Korea News / Yu Ji-in) It was found that when small-sized focused ultrasound (IMD10) treatment is added to standard chemotherapy for cancer patients, low tumor response is improved.
IMG announced the results of a clinical trial on pancreatic cancer patients using a portable, compact, non-thermal focused ultrasound system (IMD10) developed to improve the low tumor response to standard chemotherapy at the 2024 European Society for Medical Oncology (ESMO) Congress.
According to data released by Professor Jae-Young Lee of the Department of Radiology at Seoul National University Hospital, who is the clinical trial leader, the results of a randomized comparative clinical trial targeting 30 patients with locally advanced or borderline resectable pancreatic cancer showed that compared to the standard chemotherapy FOLFIRINOX monotherapy group, the target tumor size was reduced by 1.8 times in the IMD10 concurrent treatment group, and the objective response rate (ORR) was improved by 1.7 times.
“IMD10 is expected to improve the low tumor response to standard drug therapy in pancreatic cancer patients through enhanced drug delivery,” said Lee Hak-jong, CEO of IMG. “It has high therapeutic applicability as it was developed as a small, portable device that can be easily applied to patients in a hospital environment where anticancer drug treatment is underway.”
Meanwhile, “We plan to have a preliminary meeting with the US FDA to discuss whether IMD10 can be reviewed for product approval as a Class 2 (De Novo) medical device by synthesizing non-clinical and clinical results,” he said, adding, “We will expand the application of IMD10 to other intractable solid cancers such as soft tissue sarcoma.”
IMGT is a bio venture founded in 2010 by Professor Lee Hak-jong of Seoul National University College of Medicine. It is researching and developing a new concept of treatment method that can be applied to various intractable cancers including pancreatic cancer and brain nerve diseases by combining focused ultrasound technology and nanoparticle technology. IMGT explained that it is focusing on developing a safer therapeutic ultrasound device by utilizing the non-thermal effect of high-intensity focused ultrasound energy.
IMGT is a bio venture founded in 2010 by Professor Lee Hak-jong of Seoul National University College of Medicine. It is researching and developing a new concept of treatment method that can be applied to various intractable cancers including pancreatic cancer and brain nerve diseases by combining focused ultrasound technology and nanoparticle technology. In particular, it has technological excellence in developing a safer therapeutic ultrasound device using the non-thermal effect of high-intensity focused ultrasound energy, and is also developing new treatments for chronic pain and brain nerve diseases in addition to cancer treatment. The company was listed on KONEX in July 2023.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
